Latest Health News

Sprintex has locked in A$30 million in distribution agreements across the UK, Turkiye, and India, while advancing its innovative G25 Jet Blower launch, signaling a strong growth trajectory in energy-efficient technologies.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Ardea Resources reports robust financial health and significant progress on its Kalgoorlie Nickel Project’s Definitive Feasibility Study, fully funded by a Japanese consortium. The company strengthens its leadership and advances ESG-aligned development of a globally significant nickel-cobalt resource.

Butn Limited reported a modest net cash increase from operating activities in the December 2024 quarter, ending with a strong cash balance of $16.8 million. The fintech company’s latest cash flow report reveals ongoing investment and notable payments to related parties.

Platina Resources reports promising gold mineralisation at its Challa Gold Project and secures a government grant to fund deep drilling at Xanadu, maintaining a strong cash position of $12.3 million.

Mayfield Group Holdings has declared a $5 million special dividend alongside its interim payout, signaling robust financial health and confidence in sustained growth.

London City Equities Limited reports a robust 12% increase in its investment portfolio for the half year ending December 2024, driven by strong Fiducian Group performance and strategic share sales, enabling higher dividend payouts despite ongoing legal challenges.

Argosy Minerals has reported significant progress on its flagship Rincon Lithium Project, including an upgraded mineral resource estimate and advancing engineering and feasibility studies toward a 12,000tpa lithium carbonate operation.

Pacific Edge announces a two-month delay in the Medicare Local Coverage Determination for its genetic oncology tests, extending the effective date to April 24, 2025. This extension follows the company’s active engagement with US regulatory bodies.

Oneview Healthcare reported a robust Q4 2024 cash flow update, bolstered by a significant equity raise and expanding partnerships, positioning the company for accelerated growth in 2025.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

8VI Holdings Limited has confirmed its voluntary delisting from the ASX, reporting a challenging quarter marked by declining cash reserves and a strategic pivot towards preventive care that is yet to yield significant revenue.